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http://www.biomedcentral.com/1471-244X/14/247RESEARCH ARTICLE Open AccessPsychometric properties of the self-report version
of the Quick Inventory of Depressive Symptoms
(QIDS-SR16) questionnaire in patients with
schizophrenia
Irene M Lako1, Johanna TW Wigman2,3, Rianne MC Klaassen4, Cees J Slooff5, Katja Taxis1,
Agna A Bartels-Velthuis2* and GROUP investigatorsAbstract
Background: Self-report instruments for the assessment of depressive symptoms in patients with psychotic
disorders are scarce. The Quick Inventory of Depressive Symptoms (QIDS-SR16) may be a useful self-report instrument,
but has received little attention in this field. This paper aimed to test the psychometric properties of the QIDS-SR16
questionnaire in patients with a psychotic disorder.
Methods: Patients diagnosed with a psychotic disorder from health care institutions in The Netherlands were included
in the study. Depressive symptoms were assessed with the QIDS-SR16 and the Calgary Depression Scale for Schizophrenia
(CDSS). Psychotic symptoms were assessed with the Positive and Negative Syndrome Scale (PANSS) and extrapyramidal
symptoms (EPS) with three EPS rating scales. Spearman’s correlation coefficients were used to compare the total score of
the QIDS-SR16 with the total scores of the CDSS, PANSS-subscales and EPS rating scales.
Results: In a sample of 621 patients with psychotic disorders, the QIDS-SR16 showed good internal consistency (α= 0.87).
The QIDS-SR16 correlated moderately with the CDSS (r = 0.44) and the PANSS subscale for emotional distress (r = 0.47).
The QIDS-SR16 showed weak correlation with the PANSS subscale for negative symptoms (r = 0.28) and minimal correlation
with EPS rating scales (r = 0.09-0.16).
Conclusions: The QIDS-SR16 may reliably assess depressive symptoms in patients with psychotic disorders, but its
concurrent validity with the CDSS was rather poor in this population. We would recommend developing a new
self-report questionnaire for the assessment of depressive symptoms in patients with psychotic disorders.Background
Depressive symptoms are highly prevalent in patients
with schizophrenia, with prevalence rates estimated
between 7% and 75% [1,2]. Depressive symptoms are
present throughout all phases of the illness [3] and may
lead to a higher burden of disease and more frequent
relapses [4,5]. Screening and routine monitoring of these
symptoms may guide appropriate treatment [6,7]. De-
pressive symptoms can be difficult to distinguish from
negative symptoms and extrapyramidal symptoms (EPS),* Correspondence: a.a.bartels@umcg.nl
2University of Groningen, University Medical Center Groningen, University
Center for Psychiatry, Rob Giel Research Center, Groningen, The Netherlands
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© 2014 Lako et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orsuch as drug-induced parkinsonism [8]. Adequate
recognition of depressive symptoms, as well as regular
monitoring of symptomatic changes is essential to guide
appropriate treatment in patients with schizophrenia
[7,9]. Therefore, monitoring depressive symptoms re-
quires reliable instruments with tested validity in pa-
tients with schizophrenia. To date, the only instrument
designed for the assessment of depressive symptoms in
this patient population is the interview-based Calgary
Depression Scale for Schizophrenia (CDSS) [10]. The
CDSS is a reliable and valid instrument that is able to
distinguish depressive symptoms from negative psych-
otic symptoms and EPS [10]. However, the interview-
based assessment method has some drawbacks, such asd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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report may be as good as interview-based assessments for
monitoring change in psychopathology [11] and saves
time and costs in routine clinical practice [12]. The avail-
ability of self-report depression instruments with compar-
able reliability and validity in patients with schizophrenia
is however limited [13]. The Beck Depression Inventory-II
(BDI) is the only self-report depression instrument for
which complete information on psychometric properties
in a population with schizophrenia are available for review
[14]. Review of these properties demonstrated that the
concurrent and predictive validity of the BDI was rather
poor, perhaps because almost half of the items of the BDI
could also be interpreted as negative symptoms [13].
The Quick Inventory of Depressive Symptoms (QIDS-
SR16) is a short and easy-to-use self-report instrument
to assess depressive symptoms [15]. The QIDS-SR16 is
sensitive to symptomatic change and its psychometric
properties are good in patients with depressive disorders
[16]. Furthermore, it was found that the presence of
psychotic symptoms did not meaningfully affect the
ability of self-rating to recognize depressive symptoms in
patients with major depressive disorder [17]. To our
knowledge, the reliability and validity of the QIDS-SR16
has not been tested in patients with schizophrenia. A
question of specific interest is whether the QIDS-SR16 can
distinguish depressive symptoms from negative and extra-
pyramidal symptoms in this population (divergent validity).
Furthermore, it is unknown whether the latent structure
of the QIDS-SR16 remains one-dimensional [18,19], or that
multiple (negative symptom) dimensions can be identified
when applied in patients with schizophrenia.
The aim of the current study is to evaluate the psycho-
metric properties of the QIDS-SR16 in a population of
patients with psychotic disorders. We examined (1) the
internal consistency of the QIDS-SR16, (2) the dimen-
sional structure, (3) the concurrent validity with other
depression instruments and (4) the divergent validity
with negative and extrapyramidal symptoms.
Methods
Subjects
Subjects were patients participating in the Genetic Risk
and Outcome of Psychosis (GROUP) study, a naturalistic
longitudinal cohort study. The longitudinal GROUP study
is conducted by four academic centers in the Netherlands
and a large number of mental health institutes in the
Netherlands and the Dutch speaking region of Belgium.
The GROUP study was approved centrally by the Ethical
Review Board of the University Medical Center Utrecht
and all participants gave written informed consent in
accordance with the committee’s guidelines. For a detailed
overview of the GROUP structure, data flow, quality
control, recruitment, sample characteristics of the studiedpatients and training procedures of the assessors see
Korver et al. [20]. The current data was collected during
the second assessment of the study, three years after the
baseline assessment (GROUP data release 3.02). Patients
were included in the current study if they had a diagnosis
of a psychotic disorder according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM-IV) criteria
[21] and if data of the following rating scales were com-
plete: the QIDS-SR16, CDSS, and Positive and Negative
Syndrome Scale (PANSS) [22], Abnormal and Involuntary
Movements Scale (AIMS) [23] and Barnes Akathisia
Rating Scale (BARS) [24]. These rating scales were
administered by trained research assistants.
All research assistants were very well trained in ad-
ministering the instruments. Data on interrater reliability
of the GROUP study were not yet available for the sec-
ond assessment, but the intraclass correlation coefficient
of PANSS total score of the first assessment was 0.946
(95% confidence interval 0.758 to 0.996) [20].
Two weeks before the assessment patients were sent
the self-report questionnaires (i.c., QIDS-SR16), with the
request to bring them along completed to the assess-
ment. Interviews and tests were administered in a fixed
order (i.c., PANSS, CDSS, EPS scales), normally on the
same day.
Measures
Patients completed the self-report version of QIDS-SR16
to assess depressive symptoms [15] (see for English
version in Additional file 1, for multiple translations and
scoring instructions see http://www.ids-qids.org/). The
measure consists of 16 items, covering nine depressive
symptom domains. Each domain score is based on the
highest score on the pertaining items. Domain scores
and item scores are rated on a Likert scale ranging from
0 to 3, with a total score range of 0–27. For an interpret-
ation the QIDS-SR16 total score see http://www.ids-qids.
org/. Depressive symptoms were also assessed by the
9-item CDSS interview [10]. Item scores are rated on a
Likert scale ranging from 0 to 3. A sum score above 4
out of 27 on the CDSS was used as cut-off scores to
establish the presence of a minor depressive episode or
clinical depression [10,25]. Psychotic symptoms were
assessed with the PANSS [22,26]. For the current ana-
lyses, we used the five-factor model of the PANSS [27],
consisting of the subscales ‘positive symptoms’, ‘negative
symptoms’, ‘disorganization symptoms’, ‘excitement’ and
‘emotional distress’. Item scores of the PANSS range
from 1 (not present) to 7 (extreme) and the subscales
scores for negative symptoms range from 7–49 and 7-28
for emotional distress. Extrapyramidal symptoms were
assessed using the AIMS [23], the BARS [24] and, when
available, the ‘motor examination’ subscale of the Unified
Parkinson's Disease Rating Scale (UPDRS) [28]. The
Table 1 Patient characteristics (N = 621)
Mean (SD; range) or N (%)
Age 30.1 (7.3; 18–59)
Male (%) 478 (77%)
Education
Primary school 39 (6%)
Secondary school/high school 322 (52%)
Vocational education 150 (24%)
Vocational higher education 65 (11%)
University 45 (7%)
Illness duration (years) 7.3 (4.1; 2.0-43.1)
Age of onset first psychosis (years) 22.3 (6.7; 5–51)
Primary diagnosis
Schizophrenia 398 (64%)
Schizoaffective disorder 80 (13%)
Schizophreniform disorder 37 (6%)
Delusional disorder 14 (2%)
Brief psychotic disorder 13 (2%)
Psychotic disorder NOS 64 (10%)
Other psychotic disorder 15 (2%)
Antidepressantsa 81 (17%)
Antipsychoticsa







Other antipsychotics 35 (7%)
Combination therapy 65 (14%)
QIDS-SR16 (total) 6.6 (4.9; 0–26)
CDSS (total) 2.0 (2.8; 1–16)
PANSS Total 61.8 (18.9; 41–148)
PANSS-EMO (emotional distress) 13.1 (4.8; 8–33)
PANSS-NEG (negative symptoms) 12.6 (5.4; 4–41)
PANSS-POS (positive symptoms) 11.3 (5.4; 3–39)
PANSS-DIS (disorganized symptoms) 14.2 (5.1; 10–46)
PANSS-EXC (excitement symptoms) 10.6 (3.2; 2–29)
AIMS (total) 0.1 (0.2; 0–1.9)
BARS (total) 0.3 (0.6; 0–4.0)
UPDRS (subtotal motor symptoms)b 0.2 (0.1; 0–1.4)
Abbreviations: SD Standard Deviation; QIDS-SR16 Quick Inventory of Depressive
Symptomatology 16-item self-report version; CDSS Calgary Depression Scale for
Schizophrenia; PANSS Positive and Negative Syndrome Scale; AIMS Abnormal
Involuntary Movement Scale; BARS Barnes Akathisia Rating Scale and UPDRS
Unified Parkinson’s Disease Rating Scale.
a Data on medication was available for n = 481 (77%) patients.
b UPDRS ratings were available for n = 531 (85%) patients.
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ing scales were administered by the same research assist-
ant on the very same day. The self-report QIDS-SR16
was sent to the participant about two weeks prior to the
assessment, with the request to fill in the questions and
bring the questionnaire along to the research assistant.
Different rating scales were used for the assessment EPS
because each of the rating scales reflects a different sub-
set of motor symptoms. The AIMS is focused on dyskin-
esia (involuntary movements), the BARS on akathisia
(restlessness) and the UPDRS on parkinsonism. The
symptoms measured by these scales may relate them-
selves differently to depressive symptoms. For example,
depressive symptoms have also been associated with parkin-
sonism [8] and restlessness or psychomotor agitation is also
a depressive symptoms (see question 16 of the QIDS-SR16).
Statistical analyses
Psychometric properties of the QIDS-SR16 were exam-
ined using SPSS, version 16.0, and R (v.3.0.1) running in
R-studio. The internal consistency of the QIDS-SR16 was
assessed by calculating ordinal alpha, the conceptual
equivalent to Cronbach’s alpha for ordinal data [29] with
the R packages ‘psych’ [30], and ‘GPArotation’ [31]. A
value of 0.80 or higher indicated good internal
consistency [32]. Additionally, polychoric inter-item
correlations of the QIDS-SR16 were calculated. Average
values of r > 0.15 were deemed acceptable, since depres-
sive symptoms as covered by the QIDS-SR16 may repre-
sent a broad construct [33]. The dimensional structureTable 2 Mean scores on individual items of the QIDS-SR16
(N = 621)
QIDS-SR16 items Mean SD
1 Sleep onset insomnia 0.93 1.09
2 Mid-nocturnal insomnia 0.76 0.99
3 Early morning insomnia 0.41 0.86
4 Hypersomnia (excessive sleep) 1.03 0.92
5 Feeling depressed 0.65 0.76
6 Decreased appetite 0.20 0.50
7 Increased appetite 0.35 0.69
8 Weight reduction 0.39 0.79
9 Weight gain 0.36 0.77
10 Concentration/decision making 0.64 0.81
11 Self-view 0.69 1.09
12 Suicide ideation 0.32 0.68
13 General interest 0.40 0.75
14 Energy level 0.55 0.77
15 Feeling slowed down 0.35 0.72
16 Feeling restless 0.49 0.82
Abbreviations: SD Standard Deviation.
Figure 1 Scree plot of obtained eigenvalues of the QIDS-SR16, compared to eigenvalues based on random data.
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analysis to determine how many principal components
should be extracted from the data (PCA) [34]. In parallel
analysis, the factors are retained as long as the ith eigen-
value from the actual data is greater than the ith eigen-
value extracted from a randomly drawn dataset that is
similar to the actual dataset in its number of cases and
variables. The parallel analysis was based on the poly-
choric inter-item correlations and conducted with the
R-package ‘psych’ [30]. If a 1-component structure was
found, this would suggest that the items that are covered
by the QIDS-SR16 are best represented by one under-
lying construct, i.e. depression. The total score of the




































































Abbreviations: QIDS-SR16 Quick Inventory of Depressive Symptoms 16-item self-repoPANSS and EPS rating scales. Concurrent validity was
investigated by calculating Spearman correlations (ρ) of the
QIDS-SR16 with the CDSS and the PANSS subscale for
emotional distress. Divergent validity was examined by cal-
culating Spearman correlations of the QIDS-SR16 with the
PANSS-Negative symptoms subscale and the three EPS rat-
ing scales. Spearman correlations were used because of non-
normality of the data. Bootstrapping was used to calculate
the 95% confidence intervals (95% CI) of the correlations.
Results
Sample
Overall, 809 (72%) of the 1119 patients with a psychotic






























Table 4 Spearman correlations (95%CI) of QIDS-SR16
symptom domains with the CDSS total score
QIDS-SR16 domains Correlation
Sleep disturbance 0.22 (0.14-0.30)
Depressed (sad) mood 0.46 (0.38-0.52)
Change in appetite or weight 0.14 (0.07-0.22)
Concentration/decision making 0.27 (0.19-0.34)
Self-view 0.36 (0.28-0.43)
Suicidal ideation 0.38 (0.31-0.45)
Interest 0.33 (0.24-0.40)
Energy/fatigue 0.28 (0.21-0.35)
Psychomotor agitation/retardation 0.28 (0.20-0.35)
Abbreviations: QIDS-SR16 Quick Inventory of Depressive Symptoms 16-item
self-report version; CDSS Calgary Depression Scale for Schizophrenia.
All correlations were significant (p < .001).
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second assessment did not differ in age (F[1,1117] = 3.15;
p = 0.076), gender (χ2[1] = 0.71; p = 0.40) or duration of
illness (F[1,1032] = 3.26; p = 0.071) from those who only
completed baseline assessment. Of the 809 patients who
participated in the second assessment, 621 patients com-
pleted all questionnaires that were required for inclusion
in the current study (QIDS-SR16, CDSS and PANSS).
Demographic and clinical descriptive information of this
sample can be found in Table 1. The mean scores on the
individual items of the QIDS-SR16 are given in Table 2.
According to the CDSS, clinical depression was present
among 17% (N = 103) of the patients.
Internal consistency and dimensionality
The QIDS-SR16 showed good internal consistency
(ordinal alpha = 0.87). All individual inter-item correla-
tions were within an acceptable range of 0.19-0.63
(Table 3) with an average inter-item correlation of 0.42.
The parallel analysis results suggested that the data of
the QIDS-SR16 can be reduced to one component in this
sample (Figure 1).Table 5 Concurrent and divergent validity of the QIDS-SR16 to
QIDS-SR16
Concurrent validity QIDS-SR16 1
CDSS 0.44 (0.38-
PANSS-D 0.47 (0.41-




Concurrent validity of the QIDS-SR16 total score with other depression instruments
Values are Spearman correlation coefficients (95% CI). Significant correlations were
Abbreviations: QIDS-SR16 Quick Inventory of Depressive Symptoms 16-item self-repo
Negative Syndrome Scale, emotional distress subscale (−D) and Negative symptom
Akathisia Rating Scale and UPDRS-motor, Motor subscale of the Unified Parkinson’sConcurrent and divergent validity
The correlations of the individual domains of the QIDS-
SR16 with the CDSS ranged between 0.14 and 0.46 (Table 4).
The total score of the QIDS-SR16 correlated moderately
with the CDSS (ρ = 0.44; p < .001) and the PANSS subscale
for emotional distress (ρ = 0.47; p < .001), as displayed in
Table 5. The QIDS-SR16 showed weaker correlations with
negative symptom ratings of the PANSS (ρ = 0.28; p < .001)
and extrapyramidal symptom ratings of the AIMS (ρ = 0.09;
p < .05), BARS (ρ = 0.16; p < .001) and UPDRS-motor sub-
scale (ρ = 0.13; p < .001).
Discussion
The current study was, to the best of our knowledge, the
first to investigate the psychometric properties of the
QIDS-SR16 in a large sample of patients with psychotic
disorders. The QIDS-SR16 remained unidimensional in
the current sample, representing depressive symptoms
as an independent domain from negative symptoms and
other psychotic symptoms in patients with schizophrenia
[19,35]. Furthermore, the internal consistency of the
QIDS-SR16 was good in our patient population, and
comparable to that previously reported for the CDSS
[36]. This suggests that patients with a psychotic dis-
order are able to rate their depressive symptoms in a
reliable way [11]. The QIDS-SR16 agreed moderately
with the CDSS, suggesting conceptual differences with
the rating scale that is currently considered as the gold
standard for assessment depressive symptoms in patients
with schizophrenia.
These conceptual differences may reflect differences in
item selection between the QIDS-SR16 and the CDSS.
Unlike the CDSS, the QIDS-SR16 is not specifically de-
signed to assess depressive symptoms in patients with
psychotic disorders. Especially the QIDS-SR16 symptom
domains on ‘sleep’ and ‘appetite' showed low agreement
with the CDSS in our study. The scores on the sleep
domain were relatively high compared to other domains
of the QIDS-SR16; this was in most cases driven by thetal score
CDSS PANSS-D
0.51)** 1
0.54)** 0.59 (0.54-0.64)** 1
0.35)** 0.34 (0.28-0.41)** 0.40 (0.33-0.47)**
0.16)* 0.06 (−0.01-0.14) 0.06 (−0.02-0.14)
0.24)** 0.09 (0.01-0.16)* 0.15 (0.07-0.23)**
0.21)** 0.20 (0.13-0.28)** 0.25 (0.17-0.33)**
and divergent validity with negative symptoms and extrapyramidal symptoms.
indicated by * = p < .05; ** = p < .001.
rt version; CDSS Calgary Depression Scale for Schizophrenia; PANSS Positive and
subscale (−N); AIMS Abnormal and Involuntary Movements Scale; BARS Barnes
Disease Rating Scale.
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sive sleep and increased appetite may reflect side effects
of antipsychotics [37,38] and hence not necessarily be
related to the ‘physical’ symptoms of depression [21]. In-
deed, post hoc analysis using ordinal logistic regression
demonstrated that those patients using antipsychotics
with high antagonistic affinity for the histamine receptor
(olanzapine or clozapine) reported higher scores on
excessive sleep than patients using other antipsychotics
(OR [95%CI] = 1.88 [1.31-2.68]). Similarly, patients using
olanzapine or clozapine were more likely to report in-
creased appetite (OR [95%CI] = 1.94 [1.28-2.95]). It can
be argued that antipsychotic side effects confounded
changes in sleep and appetite as measured by the QIDS-
SR16 in the current sample. In contrast, the CDSS mea-
sures ‘early awakening’ and ‘morning depression’ as a
proxy for the physical symptoms of depression, in a way
less sensitive to confounding by antipsychotic side ef-
fects. Another conceptual difference is that the CDSS and
other self-report questionnaires like the Center of Epidemio-
logic Studies-Depression [39], but not the QIDS-SR16, cover
hopelessness. Patients with schizophrenia may be prone to
psychological depressive symptoms like hopelessness and
self-depreciation, possibly related to demoralization in re-
sponse to the severe mental illness [40]. Thus careful item
selection targeting only those depressive symptoms specific
for patients with a psychotic disorder may be relevant for
the validity of a self-report depression instrument in this
population.
Although there was some overlap, the QIDS-SR16
discriminated depressive symptoms from negative symp-
toms in an acceptable way, in line with previous work
on the full 30-item Inventory of Depressive Symptoms
(IDS) in a mixed population of patients with schizophrenia
and bipolar disorder [41]. In addition, a latent factor for
negative symptoms was not identified for the QIDS-SR16,
despite that several items overlap with negative symptoms,
such as of concentration difficulties (question #10), lack of
interest (#13) and lack of energy (#14). The current results
suggest that, although the QIDS-SR16 may partly tap into
the negative symptom dimension and thus should be
interpreted with care, its divergent validity is acceptable in
patients with psychotic disorders.
An unexpected result is the relatively high correlation of
the CDSS with negative symptoms in comparison to previ-
ous reports of the CDSS in patients with schizophrenia
[13]. Some correlation with negative symptoms is accept-
able, as patients may often experience both negative and
depressive symptoms at the same time [42]. Another caveat
when interpreting the current results is that the majority of
the patients had low EPS ratings. The relatively young and
possibly well stabilized sample of patients may explain the
rare presence of EPS, as previously described for the base-
line measurement of the current sample [43]. We thereforeremain inconclusive about the divergent validity of the
QIDS-SR16 with respect to the extrapyramidal symptoms
in this population.
An important strength of the study is its large sample
size. A limitation of the study design may be that the
same research assistant rated both the CDSS and the
PANSS interview. This may have led to an overesti-
mation of the correlation between the CDSS and the
PANSS subscale for emotional distress, because of prior
knowledge of the raters based on the previous interview.
Therefore, the PANSS subscale for emotional distress
does not necessarily outperform the QIDS-SR16 on its
concurrent validity with the CDSS.
To conclude, we showed that patients with a psychotic
disorder can reliably rate their depressive symptoms by
means of the self-report. However, despite the fact that
the QIDS-SR16 can provide clinicians with useful add-
itional and clinically relevant information, we would not
recommend applying the QIDS-SR16 for the assessment
of depressive symptoms in this population, based on the
poor concurrent validity of the QIDS-SR16 with the CDSS.
Future research may focus on the development of a new
self-report instrument, especially designed to assess de-
pressive symptoms in patients with psychotic disorders.
Conclusions
Seventeen percent of patients with psychotic disorders
suffered from depressive symptoms. Although the Quick
inventory of Depressive Symptoms (QIDS-SR16) may
provide unique and clinically relevant information on
depressive symptoms, this self-report instrument is not
suitable for the use in patients with psychotic disorders.
There is a need for a new self-reporting instrument
covering depressive symptoms specific for patients with
a psychotic disorder.
Additional file
Additional file 1: The Quick Inventory of Depressive
Symptomatology (16-Item) (Self-Report) (QIDS-SR16.).
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